with us
together we’re making a difference

News Releases

Sep 19, 2023 |

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023 |

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Aug 07, 2023 |

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

Aug 02, 2023 |

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Jul 30, 2023 |

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

Jul 27, 2023 |

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

Jul 24, 2023 |

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

May 24, 2023 |

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

May 16, 2023 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2023 |

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
Displaying 1 - 10 of 18
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2023 Annexon Inc. All rights reserved.